Generate Platform
Pioneering generative biology to create breakthrough medicines with AI.
Executive Summary
The Generate Platform leverages machine learning and biological engineering to design and optimize novel proteins for therapeutic applications. It is utilized by Generate:Biomedicines' scientists and strategic partners to accelerate drug discovery and development. The platform's key business value lies in its ability to rapidly generate precise therapeutic candidates, address historically undruggable targets, and fundamentally shift drug development from trial-and-error to programmable biology.
Use Cases
- Designing novel antibodies and peptides for specific therapeutic targets.
- Generating enzymes with enhanced processivity and specificity for industrial or therapeutic applications.
- Creating 'stealth' proteins that are invisible to the immune system to improve drug efficacy and reduce side effects.
- Developing therapeutics for challenging disease areas such as immunology, oncology, and infectious diseases (e.g., SARS-CoV-2).
- Addressing historically undruggable or hard-to-drug targets with novel protein designs.
- Optimizing therapeutic molecules for improved patient experience, such as extended half-life and reduced dosing frequency.
Features
Visibility
- Integrated R&D Data Platform: A cohesive platform leveraging industry best practices for managing all R&D data, from design variants to assay results.
- Digital Hand-off and Tracking: Seamless digital hand-off of design variants to protein engineering and tracking of samples through each step of the process.
- Centralized Data Management: Data from biophysical characterization, developability, and functional assays are centralized, organized, and managed to be findable and accessible.
Intelligence
- De Novo Protein Generation: Ability to create entirely new proteins and DNA sequences without relying on existing biological templates.
- Multi-modal Therapeutic Design: Generates medicines across various modalities, including antibodies, peptides, enzymes, and antibody-drug conjugates (ADCs).
- Targeted Protein Optimization: Refines proteins for specific therapeutic functions and properties like extended half-life, improved potency, and reduced immunogenicity.
- Generative Protein-Protein Interaction: Machine learning models can generate protein complexes, including antibodies targeting defined epitopes and functional antibodies.
Support
- Dedicated Scientific and Technical Teams: Internal machine learning, biological engineering, and medicines teams focused on developing computational models and experimental validation.
- Collaborative Partnership Model: Engages in strategic collaborations with other drug makers and research institutions, implying close support for joint projects.
Technical Specifications
- Architecture
- Cloud-native SaaS with an integrated dry and wet lab informatics layer
- Deployment
- Cloud/SaaS
- Authentication
- Not specified, likely enterprise-grade SSO/MFA
- API Available
- Yes
- MCP Server
- No
Infrastructure
- AWS
AI/ML Stack
- Machine Learning
- Generative AI
- Diffusion Models
Integrations
- Protein Synthesis
- High-Throughput Screening
Security & Compliance
Encryption: Not explicitly detailed, but implied by 'reasonable technical measures'
Pricing
- Model
- Custom enterprise / Partnership-based
- Starting Price
- Contact sales
- Target Customer
- Pharmaceutical companies, Biotech companies, Research institutions
- Contract Type
- Multi-year partnerships, Collaboration agreements
- Free Trial
- No (credit card required)
About Generate Biomedicines
Generate Biomedicines is a therapeutics company pioneering generative biology at the intersection of machine learning, biological engineering, and medicine to create breakthrough medicines. It operates as a developer of a machine learning-powered biomedicines platform with the potential to generate new drugs across a wide range of biologic modalities.